Skip to main content
Premium Trial:

Request an Annual Quote

McKesson to Acquire HCA's Personalized Medicine Software Unit

NEW YORK — McKesson has signed an agreement to acquire personalized medicine software developer Genospace from Hospital Corporation of America (HCA).

Genospace's platform aggregates genomic and other biomedical data to help match and recruit patients for clinical trials and to guide clinical decision making. The Boston-based company was acquired by HCA's Sarah Cannon Cancer Institute in early 2017.

Irving, Texas-based McKesson said that Genospace will help its provider partners more efficiently identify the most appropriate therapies or clinical trials for their patients. It will also provide oncology data and analytics support for McKesson's planned cancer research joint venture with HCA.

The acquisition is part of a larger deal that involves the formation of a joint venture combining McKesson's US Oncology Research with the Sarah Cannon Research Institute, the research arm of Sarah Cannon.

Financial terms of the JV formation and acquisition of Genospace were not disclosed.

The Scan

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.

Neurological Outcomes Linked to Innate Immune Features After Cardiac Arrest

Researchers reporting in Med dig into immune features found a few hours after cardiac arrest that correspond with neurological outcomes.

Mouse Study Finds Circadian Rhythm-Related Gene Expression Changes Linked to Sleep Apnea

A paper in PLOS Biology reveals tissue-specific circadian rhythm and gene expression patterns in an intermittent hypoxia-based mouse model of obstructive sleep apnea.

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.